+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Efmoroctocog Alfa"

Coagulation Protein Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Thumbnail Image

Coagulation Protein Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • May 2024
  • 137 Pages
  • Global
From
Hemophilia A - Market Insight, Epidemiology and Market Forecast - 2034 - Product Thumbnail Image

Hemophilia A - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • February 2024
  • 288 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

Efmoroctocog Alfa is a type of hematological drug used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. It is a recombinant form of Factor VIII, a protein that helps the body form clots. Efmoroctocog Alfa is administered intravenously and is used to prevent and control bleeding episodes in patients with hemophilia A. It is also used to prevent bleeding during surgery and other invasive procedures. Efmoroctocog Alfa is a relatively new drug, having been approved by the US Food and Drug Administration in 2014. It is currently available in the US, Europe, and other countries. It is marketed by several companies, including Novo Nordisk, Pfizer, and Shire. Show Less Read more